Clinical Trial

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

Name: A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) — clinical trial record (NCT07700056)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).

Trial Details

NCT Number	NCT07700056
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Chronic Pruritus of Unknown Origin
Enrollment	180 participants
Start Date	2026-08-14
Primary Completion	2029-12-19 (estimated)
Study Completion	2030-04-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-13